Top Pharma Blogs
Share the Top Pharma Blogs on
Drugs.com - FDA MedWatch Alerts
Voltaren Gel (diclofenac sodium topical gel) 1% - Hepatic Effects Labeling Changes
Audience: Rheumatological healthcare professionals, pharmacists Endo, Novartis and FDA notified healthcare professionals of revisions to the Hepatic Effects section of the prescribing information to add new warnings and precautions about the... ...
Lexiva (fosamprenavir calcium) - Dear Healthcare Professional Letter
Audience: HIV/Infectious Disease healthcare professionals, cardiovascular healthcare professionals GlaxoSmithKline and FDA notified healthcare professionals of a potential association between Lexiva and myocardial infarction and dyslipidemia in HIV... ...
Valproate Sodium and related products (valproic acid and divalproex sodium): Risk of Birth Defects
Audience: Neurological and Obstetrical healthcare professionals The FDA notified health care professionals and patients about the increased risk of neural tube defects and other major birth defects, such as craniofacial defects and cardiovascular... ...
Norpramin (desipramine hydrochloride) - Dear Healthcare Professional Letter
Audience: Psychiatric healthcare professionals Sanofi-Aventis and FDA notified healthcare professionals of changes to the Warnings and Overdosage sections of the Prescribing Information for Norpramin (desipramine hydrochloride), indicated for the... ...
Meridia (sibutramine hydrochloride): Early Communication about an Ongoing Safety Review
Audience: Cardiology and endocrinology healthcare professionals FDA notified healthcare professionals and patients that it is reviewing preliminary data from a recent study suggesting that patients using sibutramine have a higher number of... ...
Vicks Sinex Nasal Spray - Recall
Audience: Consumers Procter & Gamble and FDA notified consumers of a voluntary recall of three lots of Vicks Sinex Nasal Spray in the United States, Germany and the United Kingdom. The bacteria B. cepacia was found in a small amount of... ...
AdPharm Blog
Saphris for Bipolar disorder and schizophrenia launch ad
Merck and Schering just launched Saphris, a new atypical antipsychotic for Bipolar I disorder and schizophrenia. You can see the 8-page launch ad to healthcare professionals on AdPharm. This ad and thousands more can be seen on the AdPharm gallery, the largest keyword searchable online pharmaceutical advertising gallery....
Here’s a nicely written ad for Quintiles as seen in the latest PharmaVoice edition. It has a nice rhythm to it from the onset. Nicely done. Original image available on AdPharm.net – (2949 x 1800 pixels) The new health is the rapidly morphing world of biopharma. In a world of genome mapping and...
...
...
...
...
BioPharma Today
Ranbaxy, Pfizer, Essential Drugs List, Dainippon Sumitomo - Latest From PharmAsia News
FDA Threatens Ranbaxy With Seizure And Injunction -- Pfizer Outlines U.S Downsize, BRIC Expansion -- Pfizer-Wyeth Integration In South Korea -- China Delays Essential Drugs List -- Dainippon Sumitomo Advances Pipeline ...
Coming in Monday's "The Pink Sheet" DAILY
An HHS advisory committee is proposing restrictions on gene patenting and licensing that could make it difficult for biotech companies to enforce certain patents and engage in technology transfer with universities - During its 2009 earnings call, Vertex reported that it remains on track to file an NDA for the...
Latest News from "The Pink Sheet" DAILY
GSK Argues Its Strategy Is Delivering As Still More Cuts Are Made, Including in R&D - Tamiflu Sales Boost Roche Earnings, As Genentech Merger Is Defended - Patient Testimonials Can't Go Beyond Efficacy Shown In Clinical Trials, FDA Says In Ad Letter For Lilly's Adcirca ...
Editors' Picks from the World Press
Pipeline/RD News Discovery ties immunoglobulin subtype to H1N1 flu Lancet retracts study linking autism to MMR vaccine 2 compounds could lead to additional drugs against HIV Optimer's fidaxomicin is as effective as Vancocin in late-stage study Business Finance Drugmakers fight... ...
Coming in Friday's "The Pink Sheet" DAILY
GlaxoSmithKline delivers upbeat forecast in announcing fourth quarter results - FDA cites Lilly for misleading promotion of its hypertension drug Adcirca ...
Astellas, Takeda, CSL - Latest From PharmAsia News
Astellas Increases R&D To Bridge Patent Losses -- Takeda Shifts Resources In U.S -- CSL Licenses Antibodies From Aussie Newcomer Patrys ...
Pharma Strategy Blog
Doctors increasingly close doors to drug reps, while pharma cuts ranks Pharmaceutical companies -- battered by a sluggish drug pipeline, the looming loss of blockbuster patented drugs, an economy in recession and scrutiny of their relationships with physicians -- are......
Opportunities Abound « Frederick County Biotech Community
As you may already be aware, one of the primary reasons the National Cancer Institute is building the new Riverside Research Park is to provide space for “synergistic partners” from academia and Industry to work together to cure cancer. I......
Novel therapies could improve potency of existing AIDS treatments
"The beauty and mystery of life extends down to the molecular level. The more we see, the more we can appreciate the wonder of our own nature."Prof Arthur Olson, Scripps Institute Every now and then, something lands in my Google......
Connecting Online with Patients in China - APsaA from MedPage Today
At a session at the American Psychoanalytic Association meeting here, Leli said he conducted his first Skype analysis with a Chinese patient in 2004. "When I did my first Skype analysis, I had many doubts," he said. "Will the analytic......
New trends in Pharma: Growth in emerging markets and BRIC
In December, we started a series on new trends in the pharmaceutical industry and kicked off with a review of the growth in generics. Today, we're going to take a look at the second big growth trend: emerging markets. In......
Update on Prostate Cancer therapies
It's been a while since I took a look at what's happening in the prostate cancer arena, but it seems a good time after the recent flurry on lung and colorectal cancers, especially as it's Groundhog Day :-). There are......
Drugs.com - New Drug Approvals
Labopharm Receives FDA Approval for Oleptro
LAVAL, QC and PRINCETON, NJ, Feb. 3 /PRNewswire-FirstCall/ -- Labopharm Inc. today announced the U.S. Food and Drug Administration (FDA) has approved Oleptro (trazodone hydrochloride) Extended Release Tablets, a novel once-daily formulation of... ...
MALVERN, Pa., Feb. 3 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, just announced that it has received marketing approval from the U.S. Food and Drug Administration (FDA) for Xiaflex (collagenase... ...
PHILADELPHIA, Jan. 29 /PRNewswire/ -- GlaxoSmithKline announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for a new combination regimen using Tykerb (lapatinib) as a first-line, all-oral treatment for... ...
FDA Approves Morphine Sulfate Oral Solution for Relief of Acute and Chronic Pain
Approval is part of Agency's unapproved drugs initiative SILVER SPRING, Md., Jan. 26 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Morphine Sulfate Oral Solution for the relief of moderate to severe, acute and... ...
BRIDGEWATER, N.J., Jan. 27 /PRNewswire/ -- Tibotec Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has approved a labeling update for Prezista (darunavir) tablets to include 96-week data from the ARTEMIS and TITAN... ...
FDA Approves Novo-Nordisk's Diabetes Drug Victoza
WASHINGTON, Jan. 26, 2010 -- U.S. health officials on Monday approved Danish drugmaker Novo Nordisk's once-daily injection for treating type 2 diabetes but said more safety studies are needed before it can be cleared as a first-line treatment... ...
Pharma RSS Feed
Allergan (AGN) Reports Inline Q4 Adj-EPS of $0.78; Guides Q1, FY10
Allergan (NYSE: AGN) reports Q4 EPS of $0.78, ex-items, inline with the analyst estimate of $0.77. Revenue for the quarter was $1.21 billion, which compares to the estimate of $1.16 billion. Sees Q1 adj-EPS of $0.57-$0.59, versus the analyst consensus of $0.68. Sees FY10 adj-EPS of... Street Insider...
Biotech Stocks: Drug stocks dip; Allergan zigzags
BOSTON (MarketWatch) -- Drug stocks dipped Thursday while shares of Allergan Inc. zigzagged after the company issued a weaker-than-expected 2010 financial forecast.The NYSE Arca Pharmaceutical Index /quotes/comstock/10t!drg.x (DRG 304.84, -4.36, -1.41%)... Marketwatch - Drug stocks dip; Allergan zigzags Ticker - Banco Santander, GlaxoSmithKline Net Rises BioSpace -...
MARKET SNAPSHOT: U.S. Stocks Broadly Lower As Pfizer Disappoints
U.S. stocks fell Wednesday, led by the health-care sector as investors were disappointed by Pfizer's latest earnings and guidance, along with a smaller- than-expected rise in U.S. service-sector activity.The Dow Jones Industrial Average (DJI) fell 47 points, or 0.5%, to 10,250. Pfizer Inc.... Marketwatch - US Stocks Tumble,...
Lilly's Cialis price hikes didn't dent demand
One of the more interesting parts of Eli Lilly's Q4 earnings report was the section on Cialis, the ED drug. Lilly has doubled its price since its launch, yet that hasn't dampened demand. Report More information about formatting options BNET Pharma - Lilly Learns a Lesson on Cialis: Price Hikes Work ...
'Dr. Nobody' Says 52% of Medical Schools Don't Ban Ghostwriting
Fifty-two percent of top medical schools have no policy prohibiting ghostwriting, according to a new study in Public Library of Science Medicine. The study was conducted by Jeffrey R. Lacasse and Dr. Jonathan Leo, whom regular readers will remember were responsible for twisting JAMA into knots... PharmaGossip - "Medical ghostwriting is...
UPDATE: Cephalon To Buy Swiss Drug Maker Mepha For $590 Million
NEW YORK -(Dow Jones)- Cephalon Inc. (CEPH) agreed to acquire Swiss drug maker Mepha AG for about $590 million in a deal that will double the size of the biopharmaceutical company's international business and diversify its offerings. The move comes as Frazer, Penn.-based Cephalon has been... The Wall Street Journal...
Pharma News from PharmiWeb.com
QIAGEN Unit And Pfizer Enter Into An Agreement To Develop A Companion Diagnostic For Brain Tumor Patients MANCHESTER, England...Pfizer Inc ...
GSK launches new specialist unit to research and develop medicines for rare diseases
GSK launches new specialist unit to research and develop medicines for rare diseases GSK today announces the formation of a n...GlaxoSmithKline ...
Tapentadol Extended Release Data to Be Presented At American Academy of Pain Medicine Annual Meeting
Tapentadol Extended Release Data to Be Presented At American Academy of Pain Medicine Annual Meeting San Antonio, TX (Februar...Johnson & Johnson ...
GSK - Pharma Boss Aims For 14% Returns On Late Stage Pipeline
GSK - Pharma Boss Aims For 14% Returns On Late Stage PipelineGSK - Pharma Boss Aims For 14% Returns On Late Stage PipelinePR Ne...GlaxoSmithKline ...
Full Year 2009 results date notification – 19 February 2010
Full Year 2009 results date notification – 19 February 2010 February 4, 2010 – Shire plc (LSE: SHP, NASDAQ: SHPGY),...Shire ...
Global SWIFT Studies Will Evaluate Safety and Efficacy of CSL Behring's Biostate(R) for von Willebrand Disease and Hemophilia A...
Drugs.com - New Drug Applications
FDA Accepts Javelin Pharmaceuticals' Dyloject New Drug Application for Formal Review
NDA for Management of Acute Moderate-to-Severe Pain Includes Data from 16 Clinical Studies CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 2, 2010 - Javelin Pharmaceuticals, Inc., a leading developer and marketer of specialty pharmaceutical products for... ...
Teva Announces FDA Accepts BLA for XM02
JERUSALEM--(BUSINESS WIRE)--Feb 2, 2010 - Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing Teva's Biologics License Application (BLA) for XM02, a... ...
Protalix Announces NDA Submission Update for taliglucerase alfa for the Treatment of Gaucher Disease
CARMIEL, Israel, Feb. 2 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (NYSE Amex: PLX) announced today that, in connection with the New Drug Application (NDA) filed by the Company in December 2009 for taliglucerase alfa for the... ...
FDA Extends PDUFA Action Date for Stedesa New Drug Application
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Jan 27, 2010 - Sepracor Inc. today announced that it has received notification from the U.S. Food and Drug Administration (FDA) that the agency now anticipates completing its review of the... ...
FDA Issues Complete Response Letter for Low Dose Oral Contraceptive WC 3016
ARDEE, Ireland, Jan. 27 /PRNewswire-FirstCall/ -- Warner Chilcott plc announced today that it has received a complete response letter from the U.S. Food and Drug Administration (FDA) to its New Drug Application submitted in March 2009 for its... ...
Somaxon Provides Update on New Drug Application for Silenor for the Treatment of Insomnia
Resubmission has been filed, with 2 month review cycle SAN DIEGO--(BUSINESS WIRE)--Jan 21, 2010 - Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary... ...
Pharmaceutical Industry | Processing & Engineering: Knowledge, News and Analysis | Pharmaceutical Manufacturing
Biotech Responds to Dramatic Changes to Innovate in 2010 and Beyond
A series of articles include 'Partners in Survival: Biotech executives respond to the dramatic changes in the world,' 'The Year that Wasn’t: Even when raising money is hard, having a revenue-generating business can ensure longevity,' and '10 Fellow Travelers: Big Pharma’s move toward targeted therapeutics is fueling dealmaking between drug...
FDA Aims to Identify Risky Food, Drug Imports
...
Bristol-Myers Squibb to Freeze Salaries in 2010
...
The manufacturer’s global rollout of a centralized MES system will not happen quickly or easily, but is already resulting in error and deviation reductions in the 80%-90% range....
Teva, Amgen Duke It Out Over Generic Biotech
...
Design for Six Sigma: A Potent Supplement to QbD
The tools of Design for Six Sigma help development teams to find the “vital few” and build on the strengths of Quality by Design....
Saturday, 6 February 2010
Dow Reports Increase In Q4 Sales
Dow has reported a net income from continuing operations of $178m for the fourth quarter of 2009, compared to the net loss from continuing operations of $1.55 billion in the fourth quarter of 2008....
Lanxess To Establish New Formalin Facility In Germany
Lanxess is planning to establish a new facility for formalin production at its site in Krefeld-Uerdingen, Germany. The specialty chemicals group will then no longer be dependent on buying in the feedstock, which it needs for the production of trimethylolpropane (TMP)....
Siegfried To Create Functional Organization
Siegfried Group will be introducing a functional organization to replace its current two-division structure, effective March 1, 2010. The new structure is a result of strategic adjustments approved in the summer of 2009. Siegfried will increasingly market its two core capabilities, namely the development and production of active pharmaceutical ingredients...
Braskem Takes Over Sunoco Chemicals
Braskem, a resin producer in the Americas, has signed an agreement with Sunoco wherein the former acquires the polypropylene (PP) business of Sunoco Chemicals. Sunoco will receive $350m for the shares in Sunoco Chemicals (PP assets), upon closing, within 60 days....
Actavis has sold Norgesplaster, its manufacturing facility for plasters and athletic tape and adhesive coating, in Vennesla, Norway, to a newly formed entity, Norgesplaster AS. Norgesplaster AS is a legal entity owned by private Norwegian investors. The transaction covers all assets and contracts related to Norgesplaster....
National Patient Safety Agency Alerts Vaccine Storage
Cool-Tel has reported that the alert issued on the 21st of January from the National Patient Safety Agency requires all NHS organisations to ensure that they implement appropriate procedures for monitoring and responding to alerts in vaccine cold storage by July 2010....
Pharma QbD -
PAT and QbD for Biopharmaceuticals
Date: 05/25/2010 End: 05/26/2010 Timezone: Developing a secure in-house strategy for PAT and QbD application for biopharmaceutical products. read more...
Design for Six Sigma: A Potent Supplement to QbD
The tools of Design for Six Sigma help development teams to find the “vital few” and build on the strengths of Quality by Design. read more...
2010 PDA/FDA Joint Regulatory Conference
Date: 09/13/2010 End: 09/15/2010 Timezone: The PDA/FDA Joint Regulatory Conference offers the unique opportunity for you to join FDA representatives and industry experts in face-to-face dialogues. read more...
Date: 03/15/2010 End: 03/19/2010 Timezone: Join industry and regulatory peers at this meeting to examine manufacturing best practices and strategies to maximize your company’s efficiency and productivity, while delivering safe and reliable drugs to patients. read more...
Spare Parts: Waters Releases 2010 Supplies Catalog
The catalog includes listings of quality parts, chromatography columns, and other key supplies. read more...
Understanding the Basics of Peptide and Protein Manufacturing
A look at the applications and markets for these fundamentally different large molecules. read more...
PharmaGossip
AstraZeneca's Seroquel sparks more than 20,000 lawsuits | WHYY
via whyy.org Posted via web from Jack's posterous ...
AstraZeneca - Seroquel: read the full transcript of the BBC File on 4 documentary
Here...
Happy Days Are Here Again…Camera pans across a cheap, glittery studio backdrop consisting of a star-spangled score board emblazoned with the names of major pharmaceutical companies. In front of the set, anonymous hired hands are gabbling into telephones while a whirling digital display on the board behind them notches...
Story...
Trivia Question - Who is the guitarist?
Answer is in "comments" section....
Drugging children - some truth from Elizabeth J Roberts MD
Prior to becoming a board-certified child and adolescent psychiatrist, Elizabeth J. Roberts, M.D. taught elementary school kids in the Chicago public school system.Here are some quotes:"It's easier, sadly, to tell a parent your child has a chemical imbalance rather than to have to confront the parent with the idea that...
Drugs.com - Clinical Trials
LEO Pharma's PEP005 Meets Primary Endpoint in Phase III Trial for Pre-Cancerous Skin Condition
BALLERUP, Denmark, Feb. 1 /PRNewswire-USNewswire/ -- LEO Pharma today announced that in a Phase III study, PEP005 (ingenol mebutate) Gel, the company's lead candidate for the topical treatment of actinic (solar) keratosis (AK) or... ...
Data sponsored by the Canadian Fabry Disease Initiative (CFDI) to be presented by Dr. Michael West, Dalhousie University CAMBRIDGE, Mass., Feb. 3 /PRNewswire-FirstCall/ -- Shire plc , the global specialty biopharmaceutical company, today... ...
Cymbalta Significantly Reduced Chronic Low Back Pain in New Study
INDIANAPOLIS, Feb. 3 /PRNewswire-FirstCall/ -- In a new study, 60 mg of Cymbalta® (duloxetine HCl) taken once daily significantly reduced chronic low back pain, as measured by the Brief Pain Inventory (BPI) average pain rating, compared... ...
CARMIEL, Israel, Feb. 4 /PRNewswire-FirstCall/ -- Protalix Biotherapeutics, Inc. (NYSE- Amex: PLX) today announced that data from its pivotal Phase III trial of taliglucerase alfa in patients with Gaucher disease will be presented at the Annual... ...
Tanezumab Demonstrated Analgesic Efficacy Across Three Pain Conditions in Phase Two Studies
SAN ANTONIO, Feb. 4 /PRNewswire-USNewswire/ -- Tanezumab, a humanized monoclonal antibody that targets nerve-growth factor, reduced pain in three common pain conditions, according to the results from three phase two studies presented today in a... ...
Researchers Identify Racial Differences in Pain Treatment Outcomes
SAN ANTONIO, Feb. 4 /PRNewswire-USNewswire/ -- Findings from a retrospective analysis of a three-week treatment program for chronic pain revealed African Americans experienced worse outcomes compared to a matched group of Caucasians. The research... ...
Pharma Marketing Blog
Me and about 1000 other people who "follow" @boehringerus (Boehringer Ingelheim) on Twitter lately have been getting several messages like this one:#4COPD robs people of their ability to breathe. Get screened 2 see if UR at risk & talk to your Dr about your results http://ow.ly/13VknIt's part of a huge...
Did Cephalon Pay James Mcmillen $101,650 to Help Promote Actiq for Off-Label Use?
In a recent post, I wondered why a doctor from Dillsberg, PA, a town with a total area of 0.8 square miles and only 2,063 people, would be the 5th highest paid physician on Cephalon's list of payments to physicians. That doctor -- James Mcmillen -- received $101,650 in 2009...
FDA Warns Meda Pharmaceuticals that Astelin Isn't Approved as a Cure for House Cleaning!
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health ServiceFood and Drug Administration Silver Spring, MD 20993TRANSMITTED BY FACSIMILERichard Fosko, RPh, MPH, Director Regulatory Affairs Meda Pharmaceuticals, Inc. 265 Davidson Avenue, Suite 300 Somerset, NJ 08873-4120RE: NDA #20-114ASTELIN®(azelastine hydrochloride) Nasal SprayMACMIS #18201Dear Mr. Fosko:As part of its routine monitoring and surveillance...
Is M&A Frenzy Short-Circuiting Pharma R&D?
Pfizer, "the world's premier biopharmaceutical R&D organization," plans to cut research spending by up to $3B reports this Wall Street Journal story. This, says WSJ, is "an attempt to wring efficiencies following its take-over of Wyeth without sacrificing future product development."But Kenneth "Eric" Milgram, Ph.D., former Director, Systems Biology Technologies...
Transparency Vs. Translucency in Reporting Physician Payments
"Transparency" is a word you often hear today. It's being used a lot in relation to Wall Street bonuses. It's also used by pharmaceutical companies who are reporting payments made to physicians.The latest pharma company to report its physician payments is Cephalon. "Cephalon supports transparency in its financial relationships with...
I think the elevation of "crowdsourcing" as a legitimate indication for determining drug benefits or risks in the real world is a luddite-like anti-science trend that must be counteracted.The latest example of this was just published on the Dose of Digital blog in the post "The Best Pharma Products According...
Pharma 2.0
I do not know Bertalan Mesko, MD personally but this Hungarian physician and PhD-to-be in personalized genomics publishes some of the best content related to Health 2.0 on the Web. His blog is ScienceRoll and he tweets @berci. Bertalan has assembled an incredible list of online/2.0 resources by specialty on his...
My friend and fellow social media evangelist Eileen O’Brien has launched a weekly Tweetchat about social media and pharma. I stumbled upon it on Wednesday night (1/6) and joined in near the end when Eileen mentioned AZ Helps – a sort of help desk offering from AstraZeneca that uses...
Pharma and Healthcare Social Media Wiki
I have no clue when Jonathan Richman has time to sleep or work given all of the information he gathers and publishes on his blog Dose of Digital. One of the best areas on his site is the Pharma and Healthcare Social Media Wiki. It is chock full of real-world...
Facts, figures, data. We all love to use numbers in our PPTs. Great info has trickled out over the past couple of months from one of my favorite sources – Manhattan Research. And thank you to MR for mentioning Pharma 2.0 in its white paper: How Digital is Shaping...
FDA hearings on social media in progress
The day has arrived – the big FDA hearings on social media. People are tweeting and blogging and texting and posting every single word of the testimony. It is surreal and exhausting to follow, which I only do sporadically. There will so many post-mortems on the two days I...
Activity is heating up in the social pharma arena just as the FDA meeting approaches next week. A few concrete examples of progress on the engagement front. Lilly used Twitter to promote its Oncology on Canvas competition, now in its fifth year. Lilly launched this “Expressions of a Cancer Journey Art...
Pharmainfo.net - Pharma Industry News
BRIEF: Pfizer still bidding for Ratiopharm
BRIEF: Pfizer still bidding for Ratiopharm Trading Markets - 1 hour ago There are conflicting reports about the auction for German pharmaceutical company Ratiopharm, in which Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) is among the bidders. After ... ...
Drug makers react to FDA ad scrutiny
Drug makers react to FDA ad scrutiny Pittsburgh Post Gazette - 15 minutes ago By Shannon Pettypiece, Bloomberg News Sexual innuendo is being muted in TV ads for Pfizer Inc.'s Viagra as drug makers react to added US scrutiny of promotional campaigns for medicines. Sexual ... ...
Bristol-Myers Squibb Investor's Business Daily - 19 minutes ago Please check the URL for proper spelling. If you're having trouble locating a destination on Investors.com, try visiting the Investors.com home page. ...
NovaBay Pharmaceuticals To Present At The 2010 BIO CEO & Investor Conference
NovaBay Pharmaceuticals, Inc. (NYSE Amex: NBY), a clinical stage biopharmaceutical company developing first-in-class, anti-infective compounds in the treatment and prevention of antibiotic-resistant infections, today announced that Ron Najafi, Ph.D., Chairman and Chief Executive Officer, will deliver a corporate presentation at the 12th Annual BIO CEO & Investor Conference on...
Biogen Plans First Study For Earlier Use Of MS Drug Tysabri
Biogen Plans First Study For Earlier Use Of MS Drug Tysabri read more...
In a Cross-Country Comeback, Skier With Type 1 Diabetes Named to U.S. Olympic Team
Kris Freeman hopes for first U.S. cross-country medal since 1976; health issues plagued 2006 Olympic bid INDIANAPOLIS, Jan. 19 /PRNewswire-USNewswire/ -- Kris Freeman is back in the hunt for an Olympic medal in Vancouver after being named today to the U.S. ski team following a disappointing finish a ...